ReviewJournal of clinical pathology2004
Membrane associated proteases and their inhibitors in tumour angiogenesis.
Review in Journal of clinical pathology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 110 citations in OpenAlex.
- Bioinformatic Analysis of Contrasting Expression Patterns and Molecular Interactions of TIMPs in Breast Cancer: Implications for Tumor Progression and Survival.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Article
- Review
- Effects of the serine protease inhibitor rBmTI-A in an experimental mouse model of chronic allergic pulmonary inflammation.Scientific reports · 2019Article
- MMP-2 silencing reduces the osteogenic transformation of fibroblasts by inhibiting the activation of the BMP/Smad pathway in ankylosing spondylitis.Oncology letters · 2018Article
- Unraveling the Role of Angiogenesis in Cancer Ecosystems.Frontiers in oncology · 2018Review
- Membrane-anchored proteases in endothelial cell biology.Current opinion in hematology · 2016Review
- Cyclic thrombospondin-1 mimetics: grafting of a thrombospondin sequence into circular disulfide-rich frameworks to inhibit endothelial cell migration.Bioscience reports · 2015Article
- ATF3 functions as a novel tumor suppressor with prognostic significance in esophageal squamous cell carcinoma.Oncotarget · 2014Article
- Inflammatory breast cancer: New factors contribute to disease etiology: A review.Journal of advanced research · 2014Review
- Lentiviral vector-based therapy in head and neck cancer (Review).Oncology letters · 2014Article
- Matriptase-2 inhibits HECV motility and tubule formation in vitro and tumour angiogenesis in vivo.Molecular and cellular biochemistry · 2013Article
- The critical role of dysregulated FOXM1-PLAUR signaling in human colon cancer progression and metastasis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Time-dependent biological differences in molecular markers of high-grade urothelial cancer over 7 decades (ras proteins, pTEN, uPAR, PAI-1 and MMP-9).Virchows Archiv : an international journal of pathology · 2012Article
- Perlecan modulates VEGF signaling and is essential for vascularization in endochondral bone formation.Matrix biology : journal of the International Society for Matrix Biology · 2012Article
- Regulation of proteinases during mouse peri-implantation development: urokinase-type plasminogen activator expression and cross talk with matrix metalloproteinase 9.Reproduction (Cambridge, England) · 2011Article
- Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor.International journal of cancer · 2011Article
- Angiogenesis and Proteinases: Influence on Vascular Morphogenesis, Stabilization and Regression.Drug discovery today. Disease models · 2011Article
- Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers.Molecular cancer · 2010Article
- Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.Cellular and molecular life sciences : CMLS · 2010Review
- Epithelial-to-mesenchymal transitions and circulating tumor cells.Journal of mammary gland biology and neoplasia · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell surface proteolysis is an important mechanism for generating biologically active proteins that mediate a range of cellular functions and contribute to biological processes such as angiogenesis. Although most studies have focused on the plasminogen system and matrix metalloproteinases (MMPs), recently there has been an increase in the identification of membrane associated proteases, including serine proteases, ADAMs, and membrane-type MMPs (MT-MMPs). Normally, protease activity is tightly controlled by tissue inhibitors of MMPs (TIMPs) and plasminogen activator inhibitors (PAIs). The balance between active proteases and inhibitors is thought to determine the occurrence of proteolysis in vivo. High concentrations of proteolytic system components correlate with poor prognosis in many cancers. Paradoxically, high (not low) PAI-1 or TIMP concentrations predict poor survival in patients with various cancers. Recent observations indicate a much more complex role for protease inhibitors in tumour progression and angiogenesis than initially expected. As knowledge in the field of protease biology has improved, the unforeseen complexities of cell associated enzymes and their interaction with physiological inhibitors have emerged, often revealing unexpected mechanisms of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.